#UGA V3 DRIVER DRIVER#

The ALVAC prime was critical for the observed efficacy in RV144 as AIDSVAX administration alone did not induce protective humoral immunity in other vaccine trials 2, 3. The RV144 trial, which is so far the most successful trial of an HIV-1 vaccine, used priming with the recombinant canarypox vector ALVAC (vCP1521) followed by boosts with ALVACвЂ‰+вЂ‰AIDSVAX B/Egp120 that resulted in an estimated vaccine efficacy of 31.2% against HIV-1 infection 1.

#UGA V3 DRIVER DRIVER#

Our integrated systems biology approach has validated CREB1 as a critical driver of vaccine efficacy and highlights that adjuvants that trigger CREB1 signaling may be critical for efficacious HIV-1 vaccines.Дespite decades of intensive research, HIV-1 remains at the forefront of human pathogens for which no effective vaccine has been developed. Importantly, unlike NHPs immunized with ALVACвЂ‰+вЂ‰Alum, those immunized with ALVACвЂ‰+вЂ‰MF59, the regimen in the HVTN702 trial that showed no protection from HIV infection, exhibited significantly reduced CREB1 target gene expression. Expression of CREB1 target genes probably results from direct cGAMP (STING agonist)-modulated p-CREB1 activity that drives the recruitment of CD4 + T cells and B cells to the site of antigen presentation.

These target genes include those encoding cytokines/chemokines associated with heightened protection from simian immunodeficiency virus challenge in NHPs. Here we show that induction of the transcription factor CREB1 and its target genes by the recombinant canarypox vector ALVACвЂ‰+вЂ‰Alum augments immunogenicity in non-human primates (NHPs) and predicts reduced HIV-1 acquisition in the RV144 trial.

Development of effective human immunodeficiency virus 1 (HIV-1) vaccines requires synergy between innate and adaptive immune cells.

Uga v3 driver